Gradient AI

Transforming Teams with Cutting-Edge Generative AI Insight and Application Training

Contact us for more details

Navigating the Future with Generative AI

In times of technological transition, scientific innovations need the nourishment of commercial exposure to thrive and survive. This is true in both life sciences and AI. Embedding AI into our business processes takes time, but that window gets ever more compressed as competitive forces demand effective implementation. Our strategy is to establish generative AI upskilling  with a particular focus on MI specialists.

Gradient AI Upskilling

  • Programme is based on four sessions but can be configured individually for each client.
  • Foundations of GenAI – ​terminology, key platforms (chatGPT, Google Gemini etc.) how genAI works, prompt engineering, applications and AI agents. This provides familiarity with the current AI landscape.
  • Exploration of potential use cases compatible with departmental objectives –identify those operational tasks that are priorities for the team and where GenAI poses a credible opportunity.  
  • Explore how GenAI applications, such as assistants, should be specified and address issues such as ethics and security.  
  • Review & future potential – ​evaluate how developments can be incorporated by organisations in this fast-moving environment and ensure that the skills of employees are maintained.
request details

What can AIMI do?

AIMI has been developed as an assistant to address medicine information enquiries . The critical issue is to ensure that responses are reliable and their source easily identified. Whether in a busy medicines information pharmacy or a medical information function in a pharmaceutical we wanted to explore how generative AI can provide efficient answers to, often complex, problems.


Adverse drug reaction analysis from reports from the FDA Adverse Event Reporting System (FAERS)

ADRx - analyse drug side effects from FAERS

ADRx from PharmAdvisor is a unique online resource that aids healthcare professionals in accurately screening for and diagnosing adverse drug reactions.

This is accomplished this by evaluating a patient's symptoms and signs with the world's largest, publically available, voluntary reporting databases: the Food and Drug Administration's Adverse Event Reporting System (FAERS).

Results are displayed in clear tables. By using the PRR statistic, users can easily identify which drugs have a higher rate of reporting for specific side effects.

Patient benefits

Faster diagnosis: by using ADRx, clinicians can improve the time to diagnosis and reduce the number of repeat visits necessary for patients
Personalised care: ADRx is particularly useful for patients, such as the elderly, who often have multiple conditions and take multiple medicines
Reduced Risk: by comparing side effects across differents medicines, ADRx helps clinicians make more informed decisions, thereby reducing the potential for side effects.

Clinician benefits

Improved diagnostic throughput: ADRx can speed up the diagnostic process by offering immediate information about potential side effects. This enables clinicians to identify the causes of a patient's symptoms, allowing them to see more patients.
Reduced repeat visits: By aiding accurate and quick diagnoses, ADRx can minimize the need for patients to return for follow-up visits related to unresolved or misdiagnosed issues. This improves patient satisfaction and  frees up clinician time for other tasks or patients.
Improved medication response: ADRx extends the number of observed ADRs by a factor of 10 over those listed in datasheets. The analysis of this broader range of ADRs can provide prescribers with more choices of medicines.


Analyse ADRs

  • Enables immediate comparison for a specific ADR between a patients' medicines.
  • Input symptom or sign to review.
  • Input list of medicines being taken.
  • Observe proportional reporting ratio (PRR). A value greater than 1 indicates a disproportionate number of reports relative to all other medicines.
  • View PRR values for this symptom in other medicines in same class.
  • Extend ADR analysis to include similar concepts e.g. cytopenias.
  • Compare reactions for medicines with the same indication.

Risk assessment

  • For diabetic patients with asthma, for example, the risk assessment function can help identify which medicines that treat asthma have a minimal impact on blood glucose.
  • Risk assessment can be used to assess the reports for a specific ADR across a class of medicines.
  • Risk assessment can be employed when considering medicines for any condition in patients who are susceptible to specific risks.

Tabulated ADRs for all medicines

  • ADRs listed in manufacturers' datasheets are included and organised in tabular format.
  • This makes locating an ADR a simple and efficient task.
  • ADRs are linked to the associated FAERS values, giving users an objective measure of the number reports.
  • ADRs are also organised by the reaction groups.

Adverse Drug Reaction Prevalence

Recent research* indicates that around 1 in 4 patients presenting to a GP may be experiencing side effects from their medicines. This represents a major cause of morbidity and mortality. 

However, awareness of side effects is generally limited to those printed in the product’s datasheet. Computer systems may have medicine side effect tables but these are also limited by what is provided in datasheets.

FAERS data is gathered over time resulting in identification of emergent side effects. Datasheet (SPC in UK and Europe, Drug labels in the US) listed side effects, mostly observed in clinical trials,  represent about 15% of all observed potential side effects. In this respect, clinicians lack access to information that would help them identify potential problems.​ ADRx enables them to assess those side effects observed during widespread use